Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 30/100

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Thursday, May 22, 2025 2 min read
Key Takeaway: Bragar Eagel & Squire, P.C. is investigating BioAge Labs, Inc. over potential claims on behalf of long-term stockholders due to a class action complaint. This complaint follows the company's announcement that it would cease its STRIDES Phase 2 trial for azelaprag, citing safety concerns related to elevated liver transaminases in trial participants. The unexpected trial termination has led to a significant decline in BioAge's stock price, falling sharply from $20.09 to $4.65. The investigation focuses on whether the board of directors acted in the best interests of the company and its shareholders.

Market Sentiment Analysis

CONCERNS & RISKS

  • BioAge Labs is facing a class action complaint regarding potential breaches of fiduciary duty by its board of directors.
  • The discontinuation of the STRIDES Phase 2 trial for azelaprag due to safety concerns has raised significant doubts about the product's viability.
  • The stock price of BioAge dropped sharply from $20.09 to $4.65 following the announcement of the trial termination, indicating a loss of investor confidence.

Full Press Release Details

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company.
According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.
Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
If you are a long-term stockholder of BioAge, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
investigations@bespc.com

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the investigation about BioAge Labs, Inc.?

Bragar Eagel & Squire is investigating potential claims regarding BioAge's board possibly breaching fiduciary duties.

Why was BioAge's STRIDES Phase 2 trial discontinued?

The trial was halted due to safety concerns tied to elevated liver transaminase levels in participants.

What impact did the trial news have on BioAge's stock price?

BioAge's stock fell from $20.09 on December 6, 2024, to $4.65 the following day.

How can BioAge stockholders get more information?

Stockholders can contact Brandon Walker or Marion Passmore via email or phone for more info.

What is Bragar Eagel & Squire, P.C. known for?

The firm is recognized for representing investors in various complex litigations nationally.

Tags: BIOA Viatris Investor Conferences Healthcare BioAge Labs class action Bragar Eagel & Squire azalaprag
Last updated: May 22, 2025